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Abstract
Background: Sorafenib is recognized as a standard treatment for advanced hepatocellular carcinoma (HCC).
However, many patients have to adopt dose reduction or terminate the use of sorafenib because of side effects.
In addition, a large number of patients are resistant to sorafenib. Thus, it is essential to investigate the underlying
mechanisms of the resistance to sorafenib and seek potential strategy to enhance its efficacy.
Methods: The protein expression of hypoxia-inducible factors (HIF)-2α, 30-kDa HIV Tat-interacting protein (TIP30),
E-cadherin, N-cadherin, and pAMPK was detected by Western blot. Cell viability assays were performed to study
the influence of metformin and sorafenib on cell proliferation. Annexin V-FITC apoptosis assays were used to detect the
influence of metformin and sorafenib on cell apoptosis. The relationship between HIF-2α and TIP30 was studied using
gene silencing approach and chromatin immunoprecipitation assay. To investigate the effect of metformin and
sorafenib on postoperative recurrence and lung metastasis of HCC in tumor-bearing mice, the mice were orally
treated either with metformin or sorafenib once a day for continuous 37 days after the operation to remove the
lobe where the tumor was implanted. CD31, Ki67, and TUNEL were examined by immunohistochemistry.
Results: Our study demonstrated that metformin synergized with sorafenib reduced HIF-2α expression as examined by
Western blot. Gene silencing approach indicated TIP30 was upregulated after knocking-down of HIF-2α and chromatin
immunoprecipitation assay revealed that HIF-2α could bind to TIP30 promoter under hypoxic condition. Cell Counting
Kit-8 (CCK8) cell viability assay and Annexin V-FITC apoptosis assay showed that metformin in combination with
sorafenib suppressed cell proliferation and promoted cell apoptosis. Besides, combined therapy suppressed
epithelial-mesenchymal transition (EMT) process both in vitro and in vivo. Moreover, metformin in combination
with sorafenib significantly minimized postoperative recurrence and lung metastasis of HCC in orthotopic mouse
model. Combined therapy inhibited CD31 and Ki67 expression but promoted TUNEL expression.
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Conclusions: Metformin may potentially enhance the effect of sorafenib to inhibit HCC recurrence and metastasis
after liver resection by regulating the expression of HIF-2α and TIP30.
Keywords: Sorafenib, Metformin, Hypoxia-inducible factors, TIP30, Hepatocellular carcinoma
Background
Hepatocellular carcinoma (HCC) is the fifth most fre-
quently diagnosed cancer in men and the seventh in
women worldwide [1]. Surgical resection has been regarded
as the main treatment for HCC [2, 3]. However, postopera-
tive recurrence and metastasis are still the main obstacles
for long-term survival of HCC [4, 5].
Sorafenib is the first-line oral multi-kinase inhibitor act-
ing on advanced liver cancer. Some evidence suggest that
sorafenib can block Raf⁄MEK⁄ERK signaling pathway to in-
hibit tumor cell proliferation and it can also target the
tyrosine kinase receptor vascular endothelial growth factor
receptor-2 (VEGFR-2) or platelet-derived growth factor
receptor (PDGFR) to produce inhibition of angiogenesis
[6–8]. However, sorafenib has been proved to have limited
survival benefits with very low response rates because of
drug resistance [9]. Hypoxic environment in solid tumor
is one of the vital factors for the treatment of resistance
[10]. Many evidence indicate that hypoxia-inducible fac-
tors (HIFs) are essential for tumor cells to adapt to low
oxygen environments [11]. Recent research findings re-
vealed that sorafenib could reduce the expression of
HIF-1α, promoting the hypoxic response switch from
HIF-1α- to HIF-2α-dependent pathways, resulting in
upregulation of HIF-2α [12]. The high expression of
HIF-2α induced by sorafenib is the main cause for
HCC cells resistant to therapy in hypoxia [13].
It has been reported that, under certain circumstances,
anti-angiogenic drugs could heighten invasiveness and
increase lymphatic or distant metastasis [14]. Our previ-
ous results demonstrated that relatively low dosages of
sorafenib promoted HCC invasion and metastasis by
downregulating tumor suppressor gene HTATIP2, also
known as TIP30, which is a 30-kDa human cellular pro-
tein that was purified as a HIV-1 Tat-interacting protein
[15]. Until now, the relationship between HIF-2α and
TIP30 has yet not been reported.
Metformin is a widely used drug for the treatment of type
2 diabetes [16]. Recently, some articles pointed out that met-
formin may be associated with reduced cancer incidence in
diabetic patients [17, 18], including prostate, breast, pancreas,
and liver cancer [19–22]. In addition, it was also reported
that metformin could target NLK (Nemo-like kinase) to in-
hibit non-small cell lung cancer (NSCLC) cell proliferation
and stemness [23]. Here, we showed that metformin could
increase the sensitivity of HCC cells to sorafenib and inhibit
HCC recurrence and metastasis after surgical resection.
Results
Metformin-reversed tumor cells resistance to sorafenib
in hypoxia
MHCC97H cells were incubated under hypoxia (CoCl2)
for 24 h, and then incubated with various concentrations
of sorafenib for another 48 h. Both the normoxic and hyp-
oxic cells were suppressed in a dose-dependent manner,
but the hypoxic cells were more resistant to sorafenib
treatment than the normoxic cells (Fig. 1a). Hypoxic cells
possessed a higher level of HIF-2α proteins expression
compared to the cells under normoxia which indicated
that sorafenib could promote HIF-2α expression while
metformin had little effect on the expression of HIF-2α
(Fig. 1b). In addition, the combination of metformin and
sorafenib inhibited HIF-2α expression to a large degree,
indicating that metformin could regain hypoxic cells to be
sensitive to sorafenib treatment (Fig. 1c).
TIP30 was regulated by HIF-2α at protein level under
hypoxic conditions in HCC cell lines
Our previous work demonstrated that sorafenib could
promote the invasive and metastatic potential of HCC
by downregulating the tumor suppressor gene HTATIP2
[15]. MHCC97H cell line with stable knocking-down or
overexpression of HIF-2α were established by lentivirus
infection. Several articles have suggested that TIP30
knockdown could result in delayed EGFR endocytic
degradation and prolonged phosphorylation of AKT
(Ser473) and ERK1/2 (Thr202/Tyr204), indicating that
downregulation of TIP30 enhances EGFR signaling
[24, 25]. Here, we found that knocking-down of HIF-
2α could not only upregulate TIP30 expression in
MHCC97H and Hep3B cell lines (Fig. 2a, Additional
file 1: Figure S1) but also decrease the expression
levels of EGFR and its associated downstream mole-
cules, such as phosphorylated extracellular signal-
regulated kinases (ERK) and phosphorylated AKT, as
determined by Western blot analysis (Additional file 2:
Figure S2). However, knocking-down of TIP30 could
not cause obvious changes of HIF-2α expression
(Fig. 2b). Remarkably, knocking-down of HIF-2α pro-
moted TIP30 expression (Fig. 2c) and overexpression
of HIF-2α impaired TIP30 expression (Fig. 2d). Chro-
matin immunoprecipitation (CHIP) assays were per-
formed to determine whether HIF-2α can bind to the
TIP30 promoter, MHCC97H cells were cultured for
6 h at 400 μM CoCl2 and fixed with formaldehyde, and
You et al. Journal of Hematology & Oncology  (2016) 9:20 Page 2 of 9
then cell nuclei were isolated and sonicated. The soni-
cated chromatin lysates were immunoprecipitated with
anti-IgG or anti-HIF-2α antibodies. Extracted DNA
was used to amplify a 214-bp fragment of TIP30 pro-
moter. The amplified 214-bp product was only observed
in DNA extracted from hypoxia exposed samples immu-
noprecipitated with HIF-2α antibody. No product was
amplified when nonspecific rabbit anti-IgG was used
(Fig. 2e). All these results showed that HIF-2α could bind
to the TIP30 promoter under hypoxic conditions.
Combined metformin and sorafenib therapy suppressed
EMT process and promoted apoptosis in hypoxia
To investigate whether metformin could regain tumor
cells sensitive to sorafenib, we implemented Cell Counting
Kit-8 (CCK8) cell viability assay in MHCC97H cells. The
cells were treated with metformin or sorafenib at diverse
concentrations for 48 h, and the impact at different time
points was evaluated. Metformin or sorafenib monother-
apy significantly inhibited the proliferation of MHCC97H
cells in a dose- and time-dependent manner, and combin-
ation of metformin and sorafenib could further suppress
this effect (Fig. 3a, b). We next explored the effects of
metformin and sorafenib on tumor cell apoptosis. Flow
cytometry analysis showed that metformin or sorafenib
alone had no significant effects on tumor cell apoptosis.
However, combination of metformin and sorafenib obvi-
ously induced apoptosis of MHCC97H cells (Fig. 3c). Our
previous work suggested that relatively low dosages of
sorafenib promoted HCC invasion and metastasis by
downregulating tumor suppressor gene TIP30 [15]. Re-
cent evidence revealed that decreased TIP30 expression
could lead to epithelial-mesenchymal transition (EMT),
as well as enhance motility and invasion of HCC cells
[26]. It has been noted that the EMT may play a major
role in tumor invasion and metastasis [27]. These evidence
are all in consistent with our results. We concluded that
the combination of metformin and sorafenib synergistic-
ally impeded EMT and decreased metastasis of HCC
(Fig. 3d) which indicated that metformin could enhance
the sensitivity of tumor cells to sorafenib.
Fig. 1 Metformin sensitized hypoxic tumor cells to sorafenib. a
Hypoxic tumor cells were resistant to sorafenib compared to cells
under normoxia. MHCC97H cells were treated with 400 μM CoCl2 for
24 h, then incubated with sorafenib or metformin for another 48 h.
Cell viability, assessed by the CCK8 method, was expressed as the
percent of control for different concentrations. Western blot was used
to evaluate the effect of metformin and sorafenib alone or combined
on HIF-2α. b Under CoCl2 (400 μM) treatment, metformin had slight
effect on HIF-2α protein expression, but sorafenib promoted HIF-2α
protein expression. c Combined treatment of metformin and sorafenib
noticeably minimized the expression of HIF-2α under CoCl2
(400 μM) treatment
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Metformin synergized with sorafenib to suppress
postoperative intrahepatic recurrence and lung
metastasis in orthotopic HCC implantation models
We next examined whether the growth of hepatocellular
carcinoma, implanted in their native environment in the
liver parenchyma, could also be affected by metformin
and sorafenib treatment. Orthotopic tumor xenografts
were generated as described in the methods. Fourteen
days after the orthotopic implantation, a second operation
was carried out to remove the lobe where the tumor was
implanted. Then, mice were randomly divided into four
groups. On the third day after tumor resection, the mice
were orally treated either with 0.9 % sodium chloride
(control), 30 mg/kg sorafenib (sorafenib), 200 mg/kg met-
formin (metformin), or 30 mg/kg sorafenib in combin-
ation with 200 mg/kg metformin (sorafenib +metformin)
once daily. As shown in Fig. 4a, b, the relapse of vehicle-
treated tumors grew remarkably fast 37 days after com-
mencement of treatment. In contrast, the recurrent
tumors treated with sorafenib or metformin were signifi-
cantly (both P < 0.05) smaller than vehicle-treated recur-
rent tumors. The combination of sorafenib and
metformin further suppressed recurrent tumor growth,
which were much smaller than the vehicle-treated recur-
rent tumors (P < 0.01), and significantly smaller than the
recurrent tumors treated with sorafenib (P < 0.05) or met-
formin (P < 0.05) monotherapies. Paraffin blocks of 10 %
buffered formalin-fixed samples of the lung were pre-
pared, and serial sections were cut at 5 μm and stained
with H&E to determine the presence of lung metastases.
Metastatic nodules were not significantly reduced in
sorafenib-treated mice. However, the number of metasta-
ses was remarkably decreased when treated with metfor-
min in combination with sorafenib (Fig. 4c, d).
Fig. 2 TIP30 was regulated by HIF-2α at protein level in HCC cell lines. Lentivirus infection was used to establish a stable knocking-down or
overexpression of HIF-2α in MHCC97H cell lines. The relationship between HIF-2α and TIP30 was detected by Western blot. a Knocking-down
of HIF-2α upregulated TIP30 expression. b Knocking-down of TIP30 did not influence the expression of HIF-2α. c, d Metformin in combination
with sorafenib synergistically inhibited HIF-2α protein expression and subsequently upregulated TIP30 protein expression. e MHCC97H cells
were exposed to CoCl2 (400 μM) for 6 h, and anti-HIF-2α or anti-IgG was used for immunoprecipitation. Immunoprecipitated and purified DNA
together with 1 % of input DNA were used for PCR amplification of a 214-bp product encompassing HRE region of TIP30 promoter
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Combined therapy inhibited tumor proliferation,
angiogenesis and EMT but promoted apoptosis in vivo
There were fewer Ki67 expression in the metformin or
sorafenib treatment groups compared with the control
groups, and the combination therapy had even fewer
Ki67 positive cells. Metformin or sorafenib alone re-
duced the CD31 expression, while metformin synergized
with sorafenib could further decrease tumor angiogen-
esis. A small number of TUNEL-positive cells were de-
tected in the control group, whereas plenty of apoptotic
tumor cells were detected in metformin or sorafenib
monotherapy, the combination therapy resulted in even
more TUNEL-positive cells (Fig. 5a). EMT-associated
proteins from tumor tissue were detected using Western
blot and combined therapy inhibited the process of
EMT by upregulating E-cadherin and downregulating
N-cadherin protein expression (Fig. 5b). In addition,
combined treatment groups inhibited HIF-2α expression
but upregulated TIP30 expression at protein level which
were consistent with the results in vitro (Fig. 5c).
Discussion
Surgical operation is the primary treatment for clinical
HCC patients. However, recurrence and metastasis are
the major factors leading to poor prognosis [4, 5]. Sorafe-
nib is the first-line treatment for advanced hepatocellular
carcinoma. However, resistance of tumor cells to sorafenib
is one of the main reasons for drug utilization [9]. It seems
that finding an effective way to inhibit the resistance may
improve the efficiency of sorafenib.
Hypoxia is a prevalent phenomenon in solid tumor in
which HIF-2α plays an important role. Previous results
indicated that HIF-2α was connected with tumorigenesis,
invasion, and metastasis [28, 29]. Here, we revealed that
Fig. 3 Combined treatment of metformin and sorafenib promoted HCC cells apoptosis and inhibited epithelial-mesenchymal transition process
in hypoxia. a Cells were cocultured with metformin or sorafenib under cobalt chloride treatment for 48 h. Metformin or sorafenib impaired
MHCC97H cell proliferation in a dose-dependent manner. b Cells were treated with metformin and sorafenib alone or combined at different time
points in the presence of CoCl2. Combined treatment inhibited MHCC97H cell proliferation in a time-dependent manner. c About 5 × 10
5 MHCC97H cells
were plated in 6-well plates. After treatment with metformin and sorafenib for 48 h in hypoxia, the apoptosis was detected by flow cytometry. Combined
therapy significantly promoted MHCC97H cell apoptosis. d After treatment with metformin and sorafenib for 48 h in hypoxia, EMT-associated proteins
were evaluated by Western blot. Sorafenib alone promoted the process of EMT, while combined treatment inhibited this effect in vitro
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metformin could sensitize hypoxic HCC cells to sorafenib
and synergistically suppress the expression of HIF-2α. It
has been reported that decreased TIP30 was associated
with EMT [26], and our previous results pointed out that
sorafenib promoted EMT process by inhibiting TIP30
[15]. In the present study, we found that overexpression of
HIF-2α led to downregulation of TIP30 and subsequently
promoted the process of EMT, and knocking-down of
HIF-2α had the opposite effects. In vitro CHIP assays
showed a 214-bp band was amplified immunoprecipitated
with anti-HIF-2α antibodies under hypoxic conditions.
More broadly, our data support a role for TIP30 as a
unique HIF-2α target gene involved in the regulation of
cancer recurrence and metastasis.
The previous article reported that exosome-mediated
transfer of miR-122 via microRNA (miRNA)-modified
adipose tissue-derived mesenchymal stem cells (AMSCs)
can enhance the chemosensitivity of HCC cells [30]. Our
results showed that combination of metformin and sorafe-
nib inhibited HIF-2α expression to a large degree, indicat-
ing that metformin could regain hypoxic HCC cells to be
sensitive to sorafenib treatment in vitro. Subsequently, an
orthotopic xenograft mouse model was established to ex-
plore the influence of metformin combined with sorafenib
on recurrence and metastasis after surgical resection of
HCC. The subcutaneous tumor was removed and cut into
about 2 mm3 slice for in situ tumor implantation, and we
tried to ensure the uniformity of the tumor as far as pos-
sible before implantation. But unavoidably, there may be
some disadvantages because the variations may exist in
cancer cells. Zhang et al. indicated that arsenic trioxide
(As2O3) induced HCC cancer stem cells (CSCs) differenti-
ation, inhibited recurrence, and prolonged survival after
hepatectomy by targeting GLI1 expression [31]. Here, we
found that metformin in combination with sorafenib
could significantly inhibit the recurrence and metastasis of
primary liver cancer in mice after surgical resection.
Lower dosage of sorafenib have been found to promote in-
vasion and metastasis of HCC cells [15], and we showed
that combined therapy could obviously reduce this effect.
In general, the above features of metformin and the
encouraging results presented herein warrant future in-
vestigation of the use of metformin for combating HCC,
especially in combination with sorafenib.
Conclusions
Our data indicate that a low dose of sorafenib increases
the expression of HIF-2α which downregulated the ex-
pression of TIP30 and then promotes HCC invasion and
metastasis. Metformin may potentially act as an enhancer
of sorafenib to inhibit HCC recurrence and metastasis
after surgical resection.
Methods
Cell culture and drugs
The highly metastatic human hepatocellular carcinoma cell
line MHCC97H obtained from at the Liver Cancer Institute
of Fudan University was maintained in Dulbecco’s modified
eagle’s medium (DMEM, Gibco, UK), supplemented with
10 % fetal bovine serum, 100 units/ml penicillin, and
100 mg/ml streptomycin and cultured in a 37 °C incubator
with 5 % CO2 in the air. Sorafenib (Bayer Healthcare,
Fig. 4 Metformin together with sorafenib suppressed recurrence and metastasis of HCC after surgical resection. a Recurrent tumor in different
treatment groups. b The size (mm3) of tumors was determined. c Metastatic tumor nodules were detected by HE staining in lung(100×). d Average
number of metastatic tumor nodules in lung. Error bars represent the standard deviation (*P < 0.05, **P < 0.01)
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Leverkusen, Germany) was dissolved in dimethyl sulfoxide
at a final concentration of 20 mM, and metformin (Bristol-
Myers Squibb, China) was dissolved in PBS at a final con-
centration of 1 M for in vitro assay. Small hairpin RNA
(ShRNA) construct against HIF2α (Cat. No. HSH004903-
LVRH1GP) and control (Cat. No. CSHCTR001-LVRH1GP),
lentiviral plasmid overexpress HIF-2α (Cat. No. EX-M0910-
Lv105-5), overexpress control (Cat. No. EX-eGFP-Lv-105),
and Lenti-Pac™HIV Expression Packaging Kit (Cat. No.
HPK-LvTR-20) were all purchased from GeneCopoeia
(America).
Western blot analysis
Cells were lysed with the lysate containing 25 mM Tris-
HCl (pH 7.6), 150 mM NaCl, 1 mM EDTA, 1 % Na-
deoxycholate, 0.1 % sodium dodecyl sulfate (SDS), and
1 % Triton X-100, as well as protease and phosphatase
inhibitors. Protein concentration was measured with
Bradford reagent (Sangon Biotech, Cat. No. B724DB0009).
At least 20 μg of sample was used for detecting the pro-
tein expression. The antibodies used were as follows: anti-
HIF-2 alpha/EPAS1 rabbit polyclonal antibody (1:1000,
Novus, Cat. No. NB100-122), anti-TIP30 rabbit monoclo-
nal antibody (1:1000, abcam, Cat. No. ab177961), anti-E-
Cadherin rabbit polyclonal antibody (1:1000, abcam, Cat.
No. ab15148), and anti-N-Cadherin rabbit polyclonal anti-
body (1:1000, abcam, Cat. No. ab18203).
Animals and in vivo experiment
Male BALB/c nude mice weighed 18–20 g and aged
4–6 weeks were purchased from the Animal Research
Center, Beijing, China. To construct a nude subcuta-
neous tumor model, 1 × 107 MHCC97H cells were re-
suspended in 0.2 ml PBS and injected into the left
flank of the mouse. When the tumor volume reached
about 1 cm in diameter, the subcutaneous tumor was
removed and cut into about 2 mm3 slice, and the pieces
from one tumor of one mouse were reimplanted into all
the subsequent mice. The recipient mice were anesthe-
tized with pentobarbital sodium salt (1 %, 25 mg/kg), and
a small piece of tumor was implanted into the left lobe of
the liver. Fourteen days after the orthotopic implantation,
a second operation was carried out to remove the lobe
where the tumor was implanted. Then, the mice were
Fig. 5 Metformin synergized with sorafenib to suppress angiogenesis, proliferation, and EMT but promote apoptosis in vivo. Representative images of
tumor sections were stained with antibody against CD31, Ki67, and TUNEL (magnification ×200). a Metformin in combination with sorafenib synergistically
minimized both Ki67 and CD31 expression but promoted TUNEL expression. b Combined therapy inhibited EMT at protein level which lysated from the
tumor tissue, and pAMPK expression was elevated both in metformin group and combined treatment groups. c Combined treatment of metformin and
sorafenib suppressed HIF-2α protein expression but upregulated TIP30 protein expression evaluated by Western blot
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randomly divided into four groups. On the third day,
after tumor resection, the mice were orally treated
either with 0.9 % sodium chloride (control), 30 mg/kg
sorafenib (sorafenib) [15], 200 mg/kg metformin (met-
formin) [32], or 30 mg/kg sorafenib in combination
with 200 mg/kg metformin (sorafenib +metformin) once
daily. All the drugs were dissolved in 0.9 % sodium chloride.
The mice were treated for 37 days and killed 48 h after the
last treatment. The tumor volume (V) was measured with
vernier caliper and calculated with V = 1/2(length ×width2).
The lung tissues were fixed with 10 % formaldehyde, and
the HCC tumor tissues were cut into two parts for subse-
quent fixation with 10 % formaldehyde or frozen resection.
Immunohistochemistry
The tumor tissue samples and lung tissues were fixed
by 10 % formalin, embedded with paraffin, and cut into
5-mm-thick sections. In order to observe the metastatic
node in the lung, the lung tissues were stained with
hematoxylin and eosin. For immunohistochemistry, the
tumor tissue sections were deparaffinized, rehydrated,
subsequently subjected to antigen retrieval with 121 °C
for 5 min, and incubated with 3 % H2O2 for 10 min to
inactivate endogenous peroxidase. The specimens were
blocked with 10 % goat serum for 1 h, and then incu-
bated with primary antibody of Ki67 or CD31 overnight
in 4 °C. The next day, the slice was incubated with
secondary antibody for 1 h at room temperature. Then,
the slice was colored by DAB Substrate-Chromogen
System. TUNEL was detected using the TUNEL Apop-
tosis Detection Kit (KeyGENBioTECH, China, Cat. No.
KGA7022).
Cell viability and apoptosis assay
MHCC97H cells were plated in 96-well plates at 4000
cells/well (n = 6) containing 100 μl of DMEM +10 %
FBS treated with 400 μM CoCl2 and cultured for
24 h, then incubated with sorafenib or metformin for
another 48 h. DMEM (100 μl) and CCK8 (10 μl) were
added to each well and incubated for 2 h. Then, the
absorbance was detected with a microplate reader at
a test wavelength of 450 nm.
Annexin V/PI was applied to investigate the impact of
sorafenib or metformin on cell apoptosis. After treat-
ments, the cells were added with 5 μl Annexin V and
10 μl PI staining supplied by the Annexin V-FITC Apop-
tosis Detection Kit (SANGON, Cat. No. BS6336), then the
results were measured by flow cytometry using a FACS
flow cytometer (Becton Dickinson verse, San Jose, CA).
Chromatin immunoprecipitation assay
MHCC97H cells were fixed at 37 °C for 10 min with 1 %
formaldehyde. The cells were then collected and lysed
on ice for 30 min in cell lysis buffer (50 mM EDTA, 1 %
SDS, 50 mM Tris-HCl) containing protease inhibitors
and 1 mM PMSF. Nuclear chromatin was broken into
small fragments by sonicating the nuclear lysate on ice
using a Misonix Sonicator 3000 equipped with a micro-
tip. One percent of the volume of samples (input) was
saved for the subsequent PCR analysis. The samples were
precleared with protein A Sepharose (GE Healthcare, Cat.
No. 10043746). Equal aliquots of precleared chromatin
samples were incubated overnight at 4 °C with either spe-
cific rabbit HIF-2α or nonspecific rabbit antiserum IgG.
Immune complexes were collected by incubation with
20 ml protein A Sepharose at 4 °C for 4 h. The complexes
were washed once with buffer I (1 % Triton X-100, 2 mM
EDTA, 150 mM NaCl, 20 mM Tris-HCl, 0.1 % SDS), buf-
fer II (1 % Triton X-100,2 mM EDTA, 50 mM NaCl,
20 mM Tris-HCl, 0.1 % SDS), buffer III (0.23 mM LiCl,
1 % NP40, 1 % deoxycholate, 1 mM EDTA, 10 mM
Tris-HCl), and TE buffer (10 mM Tris-HCl (pH =
8.0),1 mM EDTA), respectively. Immune complexes
were then eluted from the beads by incubation twice
under agitation at 37 °C with 100 μl of elution buffer
(0.1 M NaHCO3, 1 % SDS). The eluted material and in-
put was cross-linked at 65 °C for 6 h. Immunoprecipi-
tated DNA was purified by PCR purification kits.
Primers used for PCR correspond to the TIP30 pro-
moter region, primers: 5′ primer: 5′-CAAACTTAGG
AAGGG TCGCG-3′; 3′ primer: 5′-ATCAGAGCATC
CCACCTTCC-3′.
Statistical analysis
All data were expressed as mean ± SD. The Student t test
was used for the comparison of measurable variants of the
two groups. P < 0.05 was defined as statistically significant.
All statistical analyses were done using statistical software
(SPSS 13.0 for Windows; SPSS, Inc., Chicago, IL).
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